Lu Zhang1, Mei-Chin Hsieh2, Claire Allison3, Michael Devane4, Chindo Hicks5, Qingzhao Yu6, Lu Shi3, Jiande Wu5, Xiao-Cheng Wu2. 1. Department of Public Health Sciences, Clemson University, United States. Electronic address: lz3@clemson.edu. 2. Epidemiology Program, School of Public Health Sciences, Louisiana State University Health Sciences Center, United States; Louisiana Tumor Registry, School of Public Health Sciences, Louisiana State University Health Sciences Center, United States. 3. Department of Public Health Sciences, Clemson University, United States. 4. Department of Radiology, Prisma Health, United States; Clemson University School of Health Research, United States. 5. Department of Genetics, School of Medicine, Louisiana State University Health Sciences Center, United States. 6. Biostatistics Program, School of Public Health Sciences, Louisiana State University Health Sciences Center, United States.
Abstract
OBJECTIVES: To investigate the race-specific second primary bladder cancer (SPBC) risk following prostatic irradiation. METHODS: Louisiana residents who were diagnosed with localized prostate cancer (PCa) in 1996-2013 and received surgery or radiation were included. Patients were followed until SPBC diagnosis, death, or Dec. 2018. The exposure variable was type of treatment (radiation only vs. surgery only). The outcome was time from PCa diagnosis to SPBC diagnosis, stratified by race. Fine and Gray's competing risk model was applied with death as a competing event and adjustment of sociodemographic and tumor characteristics. We used 5 years and 10 years as lag time in the analyses. RESULTS: A total of 26,277 PCa patients with a median follow-up of 10.7 years were analyzed, including 18,598 white and 7679 black patients. About 42.9 % of whites and 45.7 % of blacks received radiation. SPBC counted for 1.84 % in the radiation group and 0.90 % in the surgery group among white patients and for 0.91 % and 0.58 %, respectively, among black patients. The adjusted subdistribution hazard ratio of SPBC was 1.80 (95 % CI: 1.30-2.48) for radiation recipients compared to surgery recipients among white patients; 1.93 (95 % CI: 1.36-2.74) if restricted to external beam radiation therapy (EBRT). The SPBC risk was not significantly different between irradiated and surgically treated among blacks. CONCLUSIONS: The SPBC risk is almost two-fold among white irradiated PCa patients compared to their counterparts treated surgically. Our findings highlight the need for enhanced surveillance for white PCa survivors receiving radiotherapy, especially those received EBRT.
OBJECTIVES: To investigate the race-specific second primary bladder cancer (SPBC) risk following prostatic irradiation. METHODS: Louisiana residents who were diagnosed with localized prostate cancer (PCa) in 1996-2013 and received surgery or radiation were included. Patients were followed until SPBC diagnosis, death, or Dec. 2018. The exposure variable was type of treatment (radiation only vs. surgery only). The outcome was time from PCa diagnosis to SPBC diagnosis, stratified by race. Fine and Gray's competing risk model was applied with death as a competing event and adjustment of sociodemographic and tumor characteristics. We used 5 years and 10 years as lag time in the analyses. RESULTS: A total of 26,277 PCa patients with a median follow-up of 10.7 years were analyzed, including 18,598 white and 7679 black patients. About 42.9 % of whites and 45.7 % of blacks received radiation. SPBC counted for 1.84 % in the radiation group and 0.90 % in the surgery group among white patients and for 0.91 % and 0.58 %, respectively, among black patients. The adjusted subdistribution hazard ratio of SPBC was 1.80 (95 % CI: 1.30-2.48) for radiation recipients compared to surgery recipients among white patients; 1.93 (95 % CI: 1.36-2.74) if restricted to external beam radiation therapy (EBRT). The SPBC risk was not significantly different between irradiated and surgically treated among blacks. CONCLUSIONS: The SPBC risk is almost two-fold among white irradiated PCa patients compared to their counterparts treated surgically. Our findings highlight the need for enhanced surveillance for white PCa survivors receiving radiotherapy, especially those received EBRT.
Authors: Montserrat Garcia-Closas; Yuanqing Ye; Nathaniel Rothman; Jonine D Figueroa; Núria Malats; Colin P Dinney; Nilanjan Chatterjee; Ludmila Prokunina-Olsson; Zhaoming Wang; Jie Lin; Francisco X Real; Kevin B Jacobs; Dalsu Baris; Michael Thun; Immaculata De Vivo; Demetrius Albanes; Mark P Purdue; Manolis Kogevinas; Ashish M Kamat; Seth P Lerner; H Barton Grossman; Jian Gu; Xia Pu; Amy Hutchinson; Yi-Ping Fu; Laurie Burdett; Meredith Yeager; Wei Tang; Adonina Tardón; Consol Serra; Alfredo Carrato; Reina García-Closas; Josep Lloreta; Alison Johnson; Molly Schwenn; Margaret R Karagas; Alan Schned; Gerald Andriole; Robert Grubb; Amanda Black; Eric J Jacobs; W Ryan Diver; Susan M Gapstur; Stephanie J Weinstein; Jarmo Virtamo; David J Hunter; Neil Caporaso; Maria Teresa Landi; Joseph F Fraumeni; Debra T Silverman; Stephen J Chanock; Xifeng Wu Journal: Hum Mol Genet Date: 2011-08-08 Impact factor: 6.150
Authors: Karel A Hinnen; Michael Schaapveld; Marco van Vulpen; Jan J Battermann; Henk van der Poel; Inge M van Oort; Joep G H van Roermund; Evelyn M Monninkhof Journal: J Clin Oncol Date: 2011-10-24 Impact factor: 44.544
Authors: Arnold L Potosky; William W Davis; Richard M Hoffman; Janet L Stanford; Robert A Stephenson; David F Penson; Linda C Harlan Journal: J Natl Cancer Inst Date: 2004-09-15 Impact factor: 13.506
Authors: Matthew J Resnick; Tatsuki Koyama; Kang-Hsien Fan; Peter C Albertsen; Michael Goodman; Ann S Hamilton; Richard M Hoffman; Arnold L Potosky; Janet L Stanford; Antoinette M Stroup; R Lawrence Van Horn; David F Penson Journal: N Engl J Med Date: 2013-01-31 Impact factor: 91.245
Authors: Ronald C Chen; Ramsankar Basak; Anne-Marie Meyer; Tzy-Mey Kuo; William R Carpenter; Robert P Agans; James R Broughman; Bryce B Reeve; Matthew E Nielsen; Deborah S Usinger; Kiayni C Spearman; Sarah Walden; Dianne Kaleel; Mary Anderson; Til Stürmer; Paul A Godley Journal: JAMA Date: 2017-03-21 Impact factor: 56.272